This new article publication from Acta Pharmaceutica Sinica B, discusses how structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity.
Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and ...
The most visible impact of AI seems to be in coding, but it could also be poised to disrupt other hard sciences.
This new article publication from Acta Pharmaceutica Sinica B, discusses how structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity.
KAIST (President Kwang Hyung Lee) announced on the 10th that a research team led by Professor Woo Youn Kim in the Department of Chemistry has developed an AI model named BInD (Bond and ...
Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results